BioStem Technologies signs $40M committed equity facility with Roth
BioStem Technologies entered a $40 million committed equity facility with Roth Principal Investments and a related Registration Rights Agreement, allowing sales of common stock over up to 36 months.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.